2024-08-25 - Analysis Report
##  REGEN Stock Analysis Report

**Company:** Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company that focuses on developing and commercializing life-changing medicines for patients with serious diseases. 

**1. Performance Analysis:**

* **Outperformance:**  REGN has significantly outperformed the S&P 500 (VOO) with a cumulative return of 106.83% compared to VOO's 71.75%. This represents a 35.1% difference, placing REGN at the 99.51% percentile of its historical performance relative to VOO.

**2. Recent Price Movement:**

* **Strong Momentum:** REGN's recent price action shows strong momentum, with its closing price of $1199.12 exceeding all moving averages:
    * 5-day MA: $1192.25
    * 20-day MA: $1130.58
    * 60-day MA: $1073.09

**3. Technical Indicators:**

* **Overbought:** The RSI of 74.67 suggests that REGN is currently overbought, potentially indicating a near-term pullback.
* **Positive Momentum:** The PPO of 0.47 confirms positive momentum, but the recent decline in relative divergence (-19.32) suggests a potential slowdown in the rate of price gains. 

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |  |
|---|---|---|---|
| 2024-08-01 | 13.25 | 3.55 B$ | **Exceeds Expectations**  |
| 2024-05-02 | 6.7 | 3.15 B$ | - |
| 2023-11-02 | 9.48 | 3.36 B$ | - |
| 2023-08-03 | 9.05 | 3.16 B$ | - |
| 2024-08-01 | 9.05 | 3.16 B$ | - |

* **Strong Q2 2024 Earnings:** The most recent earnings report showed strong EPS and revenue growth, exceeding analysts' expectations. This reflects continued success in its core products and suggests positive future prospects.

**5. Overall Analysis:**

* **Strong Performance & Growth:** REGN has consistently outperformed the market with a significant gap in performance relative to the S&P 500. Recent earnings demonstrate continued growth and profitability, supporting the strong performance. 
* **Overbought but Momentum Remains:** While technical indicators suggest overbought conditions, the positive momentum and strong earnings support further upside potential. However, the recent decline in relative divergence and potential pullback should be monitored. 
* **Caution & Potential Pullback:** Investors should be aware of the potential for a near-term correction due to the overbought conditions. However, the long-term outlook remains positive given the strong fundamentals and growth prospects.

**6. Conclusion:**

REGN remains a promising investment with a strong track record of growth and positive outlook. However, investors should be mindful of potential near-term volatility due to overbought conditions.  Continued monitoring of technical indicators and future earnings releases is recommended to manage risk and capture potential upside gains. 
